J Korean Thyroid Assoc.  2012 Nov;5(2):132-137. 10.11106/jkta.2012.5.2.132.

Anaplastic Thyroid Carcinoma - a Therapeutic Dilemma

• Chang HS

• KMID: 2095102
• DOI: http://doi.org/10.11106/jkta.2012.5.2.132

Abstract

Anaplastic thyroid carcinoma (ATC) is a rare type of malignancy of thyroid follicular cell origin. It is one of the most aggressive human cancers, and typically associated with a fatal prognosis. Most patients are presenting as locally advanced and systemically disseminated disease. A single mode of therapy, whether it is surgery, chemotherapy, or radiotherapy, fails to afford significantly favorable outcomes. While multimodality approaches may enhance the treatment response to a small degree, such implementations of these modalities are often impractical as many patients are of old age and are unable to tolerate the intensity of treatments. As in many other types of carcinomas, radical resection may be the mainstay of therapy for ATC, but surgery itself is seldom possible for this condition. Even with aggressive surgical therapy for those invasive ATCs, there is no evidence of decreased recurrence rates, while only the post-surgical morbidity rates increase. One chemotherapeutic agent that seems to demonstrate some effect against ATC is adriamycin, which is more effective when administered in combination, and is also known to act synergistically with radiotherapy. A commonly employed treatment modality is the combination therapy of adriamycin and cisplatin administration with hyperfractionated radiation therapy. Other chemotherapeutic agents proven to be effective are taxanes such as paclitaxel and docetaxel. Despite of disappointing result of conventional radiotherapy, however, hyperfractionated radiation therapy and combined chemotherapy has been suggested to improve survival rates by some institutions, while others disagree. The dismal results of conventional treatments for ATCs have stimulated the investigation for new therapeutic methods with improved outcome. There have been a number of trials of new materials or therapeutic methods. In recent studies, some trials were partially successful or promising in vitro or in vivo. The examples of these trials are; redifferentiation therapies, molecular targeted therapies, and some other miscellaneous methods. Although the observations may suggest that some of the methods may have a therapeutic effect on ATCs, or may act as an adjunct to other primary treatment modality, the efficacy and safety have not been ascertained yet in human trials, and further confirmation through in-depth studies are required.

Keyword

Anaplastic thyroid cancer; Multidisciplinary approach; Molecular targeted therapy

MeSH Terms

Cisplatin
Doxorubicin
Humans
Molecular Targeted Therapy
Paclitaxel
Prognosis
Recurrence
Survival Rate
Taxoids
Thyroid Gland
Thyroid Neoplasms
Cisplatin
Doxorubicin
Paclitaxel
Taxoids
Thyroid Neoplasms

Reference

References

1. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999; 16(1):64–9.

2. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J. 2005; 46(6):759–64.

3. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006; 13(4):453–64.

4. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997; 79(3):564–73.

5. Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996; 40(5):953–8.

6. Rivera M, Sang C, Gerhard R, Ghossein R, Lin O. Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens. Acta Cytol. 2010; 54(5):668–72.

7. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7):1330–5.

8. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985; 83(2):135–58.

9. Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg. 2007; 31(5):969–77.

10. Abate EG, Smallridge RC. Managing anaplastic thyroid carcinoma. Expert Rev Endocrinol Metabol. 2011; 6(6):793–809.

11. Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995; 17(1):41–7. discussion 7-8.

12. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998; 8(8):715–26.

13. American Joint Cancer Committee. AJCC Cancer Staging Manual. Chicago, IL, USA: AJCC. 2010.

14. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009; 16(1):17–44.

15. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med. 2010; 31(2):215–26.

16. Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr, Douglas WG, Anderson GR. et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck. 2003; 25(8):662–70.

17. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol. 2000; 157(2):671–7.

18. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C. et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab. 2002; 87(1):370–9.

19. O’Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci. 2010; 179(1):9–15.

20. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008; 93(1):278–84.

21. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010; 20(7):697–706.

22. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y. et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid. 2004; 14(12):1020–9.

23. Garcia-Rostan G, Tallini G, Herrero A, D’Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999; 59(8):1811–5.

24. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990; 66(2):321–30.

25. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM. et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001; 91(12):2335–42.

26. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H. et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998; 22(7):725–30.

27. Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg. 2011; 19(2):113–8.

28. Lu WT, Lin JD, Huang HS, Chao TC. Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma? Otolaryngol Head Neck Surg. 1998; 118(5):728–31.

29. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000; 11(9):1083–9.

30. Pushkarev VM, Starenki DV, Saenko VO, Tronko MD, Yamashita S. Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma. Exp Oncol. 2011; 33(1):24–7.

31. Satake S, Sugawara I, Watanabe M, Takami H. Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett. 1997; 116(1):33–9.

32. Sekiguchi M, Shiroko Y, Arai T, Kishino T, Sugawara I, Kusakabe T. et al. Biological characteristics and chemo-sensitivity profile of four human anaplastic thyroid carcinoma cell lines. Biomed Pharmacother. 2001; 55(8):466–74.

33. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma–treatment outcome in 75 patients. Radiother Oncol. 2009; 92(1):100–4.

34. Pudney D, Lau H, Ruether JD, Falck V. Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid. 2007; 17(12):1243–50.

35. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000; 10(7):587–94.

36. Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M. et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol. 2010; 40(6):596–9.

37. Tennvall J, Tallroth E, el Hassan A, Lundell G, Akerman M, Biorklund A. et al. Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol. 1990; 29(8):1025–8.

38. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer. 2006; 107(8):1786–92.

39. Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Inoue H, Yabuta T. et al. Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg. 2009; 32(1):47–50.

40. Higashiyama T, Ito Y, Hirokawa M, Masuoka H, Yabuta T, Fukushima M. et al. Optimal surgical procedure for locally curative surgery in patients with anaplastic thyroid carcinoma: importance of preoperative ultrasonography. Endocr J. 2010; 57(9):763–9.

41. Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther. 2011; 11(3):387–402.

42. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M. et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope. 2007; 117(4):674–9.

43. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN. et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006; 12(2):600–7.

44. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN. et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther. 2005; 4(4):632–40.

45. Hoffman SF, Guthrie TH Jr. Cerebral cysticercosis. South Med J. 1975; 68(1):105–8.

46. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J. et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. 2005; 65(9):3716–25.

47. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA. et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007; 6(6):1785–92.